Patheon, a global provider of drug development and delivery services to the pharma and biopharma industries, has completed its acquisition of an API manufacturing facility in Florence, SC, from Roche Holdings, Inc.
 
The 300,000 sq.-ft. facility has manufacturing capacity for API ranging from development to manufacturing services, expanding the company’s capacity for manufacturing highly potent compounds and adding capabilities to support solid-state chemistry, micronization, and eventually, commercial spray drying. The site has reactors ranging from 50 -11,000 liters producing multiple products simultaneously, and is compliant with regulations, such as cGMP safety and environmental standards.

The facility will serve as Patheon’s flagship U.S. API operation for commercial scale and mid-scale API production, and enhances the company’s presence in the U.S. market. This is the company’s sixth acquisition in the last five years to expand pharma development and manufacturing services.